Today: 3 June 2026
Archer Aviation stock slips despite Needham Buy call as rates stay in focus
14 January 2026
1 min read

Archer Aviation stock slips despite Needham Buy call as rates stay in focus

New York, Jan 14, 2026, 10:04 (ET) — Regular session

Archer Aviation shares slipped 0.8% to $8.40 in early trading Wednesday, despite Needham sticking with a buy rating and a $10 price target, per a report from GuruFocus.

Timing is key as air-taxi stocks have been moving like rate-sensitive plays following new U.S. inflation figures. The consumer price index climbed 0.3% in December, marking a 2.7% rise year-over-year, while core inflation edged up 0.2% for the month, according to a report.

These firms remain years away from stable revenue, making them vulnerable to shifts in rate-cut forecasts. Rising interest rates often squeeze valuations for companies with distant cash flows, a factor rattling eVTOL shares this week.

Archer dropped 4.4% on Tuesday, finishing at $8.47, down from $8.86 on Monday, the company’s investor site shows.

On Wednesday, peers showed a soft tone with mixed results: Joby Aviation slipped 2.4%, while Vertical Aerospace dropped 1.6% in early New York trading.

Archer, the eVTOL developer, is staying focused on its tech roadmap. At CES last week, it revealed plans to partner with Nvidia’s IGX Thor platform. CEO Adam Goldstein described the move as a step toward safer, smarter systems. “CES has always been a launchpad for technologies that reshape industries,” Goldstein said. Archer Aviation

Investors remain focused on tougher milestones: securing Federal Aviation Administration type certification, which means official approval of a specific aircraft design, and proving the company can produce planes at scale without constant setbacks.

The downside is straightforward and looms over the group: certification deadlines might slip, and pre-revenue companies could be pushed to return to the market for funding. Raising new equity always carries the risk of diluting shareholders, even if Wall Street remains optimistic about long-term demand.

Macro headlines offered little relief. “We expect the CPI report to show a meaningful payback after collection issues,” said Oscar Munoz, chief U.S. macro strategist at TD Securities, ahead of Tuesday’s data release. Reuters

Traders have marked the Federal Reserve’s Jan. 27-28 policy meeting as the next key event, using it to adjust their expectations for rates and the impact on high-beta growth stocks.

All eyes now turn to Archer’s upcoming earnings report, slated for around Feb. 26, per Zacks.

Latest articles

Archer Aviation trades under $7 as next test looms for air-taxi gamble

Archer Aviation trades under $7 as next test looms for air-taxi gamble

3 June 2026
Archer Aviation shares dipped below $7 premarket after closing at $6.74, as investors weigh heavy cash burn—$217.7 million Q1 net loss, $1.78 billion cash on hand—against hopes for first U.S. eVTOL flights this year; Cantor Fitzgerald cut its price target to $11 but kept an Overweight rating, while 46 disclosed risks and ongoing certification challenges cloud near-term outlook.
Broadcom’s $280 Billion AI Rally Hits Key Test

Broadcom’s $280 Billion AI Rally Hits Key Test

3 June 2026
Broadcom’s stock soared 14% in four days, adding $280 billion in value ahead of Wednesday’s earnings after Alphabet’s $80 billion equity raise spotlighted AI data-center suppliers; with options implying a 9% share move either way, investors await proof that surging AI demand is translating into real revenue growth.
J-Star Stock Moves Up After Texas Battery Update in Pre-Market

J-Star Stock Moves Up After Texas Battery Update in Pre-Market

3 June 2026
J-Star Holding Co. surged to $1.36 in premarket trading after new disclosures on its proposed $122.5 million Baytown, Texas solid-state battery plant, pushing shares above Nasdaq’s $1 minimum less than a week before a key shareholder vote on a reverse split aimed at regaining compliance.
Legend Biotech jumps 42% as traders look at results from small cancer study

Legend Biotech jumps 42% as traders look at results from small cancer study

3 June 2026
Legend Biotech shares soared 42% to $36.28 after early Phase 1 data showed all six higher-dose patients with relapsed or refractory B-cell non-Hodgkin lymphoma responded to its in vivo CAR-T therapy LB2501, with five complete responses; UBS raised its price target to $49, citing the therapy’s outlook, but the results are early and based on a small group with short follow-up.
T1 Energy Stock Falls Premarket After $32M KORE Battery Deal

T1 Energy Stock Falls Premarket After $32M KORE Battery Deal

3 June 2026
T1 Energy shares fell 1.3% premarket after announcing a $32 million KORE Power acquisition to expand into battery storage and AI data-center infrastructure, just a day after a 15.7% stock surge; Northland initiated coverage with an outperform rating and $16 target, but flagged deal execution and funding as key risks.
Saks Global files for bankruptcy: $1.75 billion financing, new CEO and a test for luxury suppliers
Previous Story

Saks Global files for bankruptcy: $1.75 billion financing, new CEO and a test for luxury suppliers

Mastercard stock dips as Trump-backed credit card cap and swipe-fee bill keep MA in focus
Next Story

Mastercard stock dips as Trump-backed credit card cap and swipe-fee bill keep MA in focus

Go toTop